Intravenous Ibuprofen for Laparoscopic Bariatric Surgery

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary objective of this study is to test hypothesis that IV ibuprofen decreases 24 hours morphine requirement using IV PCA in patients after laparoscopic bariatric surgery. Secondary objective is to determine if it decreases respiratory depression measured using RD, improves area under curve (AUC) for pain scores at rest (AUCr) and with cough (AUCa) and pressure pain threshold (PPT) (important for mobilization). Tertiary objective is to compare incidence of nausea/vomiting, sedation, itching, blood transfusion, over sedation, urinary retention, GI or surgical bleeding, renal dysfunction, time to clears and baseline activity in ibuprofen and control groups.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jacobi Medical Center
• Collaborators: Cumberland Pharmaceuticals; Sagatech Electronics Inc, Alberta, Canada
• Treatments: Ibuprofen

Criteria

Inclusion Criteria:

• Patients scheduled for laparoscopic bariatric surgery at Jacobi Medical Center

Exclusion Criteria:

• Patients with history of ibuprofen or aspirin allergy

• morphine allergy

• opioid or psychotropic medication use pre-operatively

• positive preoperative U-tox screening

• unable to sign consent and patients unable to understand or use patient controlled analgesia (PCA) or report pain intensity

• GFR <60 or history of GI bleed within 6 weeks